Arbutus Biopharma Announcement
Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial, which has been expanded to include a PD-1 monoclonal antibody, nivolumab.
Please note that . . .
This content is for paid subscribers.
Today’s Highlights
June 21, 2023